The 2 Biotechs Ramping Up Sales
The following video is part of our "Motley Fool Conversations" series, in which David Williamson, health-care editor and analyst, and Austin Smith, consumer-goods editor and analyst, discuss topics around the investing world.
In today's edition, David and Austin discuss the big Q4 pre-releases that came out ahead of the JPMorgan Annual Healthcare Conference. Positive operational updates sent shares soaring by double digits for a pair of biotechs that struggled mightily in 2011. Find out more in the video.
Biotech investors are always looking for the next runaway success. Motley Fool co-founder David Gardner has recently identified a small-cap health-care company that he believes is poised for monster returns. To find out which stock is about to reap huge profits from fundamentally changing its industry, download our exclusive special free report, "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does.
At the time this article was published Austin Smith has no positions in the stocks mentioned above. David Williamson owns shares of Dendreon. The Motley Fool owns shares of Dendreon. Try any of ourFoolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.